Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

NCT07549061 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Lung Neoplasms

Interventions

DRUG: Vebreltinib
DRUG: Chemotherapy

Sponsor

Shanghai Chest Hospital